Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.
Francis LK, et al. Among authors: roodman gd.
Clin Cancer Res. 2006 Nov 15;12(22):6826-35. doi: 10.1158/1078-0432.CCR-06-1331.
Clin Cancer Res. 2006.
PMID: 17121904